Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Attention Deficit Hyperactivity Disorder (ADHD) Market Spotlight Report 2017-2027 - Research and Markets

Research and Markets
Posted on: 09 Nov 17

The "Market Spotlight: Attention Deficit Hyperactivity Disorder (ADHD)" report has been added to Research and Markets' offering.

This Market Spotlight report covers the Attention Deficit Hyperactivity Disorder (ADHD) market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • The author estimates that in 2016, there were 175.1 million prevalent cases of attention deficit hyperactivity disorder (ADHD) in people aged 5-44 years worldwide, and forecasts that number to increase to 185.5 million prevalent cases by 2025.
  • The worldwide prevalence of ADHD among children aged 5-19 years is estimated to be 5.29%, while the prevalence among adults aged 20-44 years is estimated to be 2.80%.
  • A majority of industry-sponsored drugs in active clinical development for ADHD are in Phase II.
  • Therapies in mid-to-late stage development for ADHD focus on targets such as dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, dopamine 2 receptor, iron, metabotropic glutamate receptor subtypes such as 1, 3, 5, 7, and 8, nicotinic acetylcholine receptor, and serotonin receptors such as 5-HT1, 5-HT3, 5-HT7, and 5-HT2A. Among these therapies, Benjorna (methylphenidate) is closest to market.
  • The majority of the pipeline drugs in mid-to-late-stage development for ADHD are administered via the oral route.
  • The majority of approved drugs in the ADHD space target dopamine, dopamine reuptake, norepinephrine (noradrenaline), norepinephrine (noradrenaline) reuptake/transporter, and alpha 2 adrenergic receptor. Most of the drugs are commonly administered via the oral route, however, a few products are available in topical and intranasal formulations.
  • High-impact upcoming events for drugs in the ADHD space include the US Food and Drug Administration (FDA) decisions on New Drug Applications (NDAs), topline Phase II/III and Phase III trial results, and a patent expiration.
  • Licensing and asset acquisition activity involving ADHD drugs has been weak during 2012-17, with only 13 deals occurring over this time period. Impax Pharmaceuticals' acquisition of certain assets related to generic products from Teva and Allergan, for $586m, was the largest deal during the 2012-17 period.
  • Vyvanse's (lisdexamfetamine dimesylate) sales have ranked highest in the ADHD space during 2012-16 and are forecasted to remain the highest during the forecast period (2017-22).
  • The clinical trials distribution across Phase I-IV indicates an even distribution of trials across the phases, with 23% each in Phase I and Phase II, 33% in Phase III, and 21% in Phase IV.
  • The US has a substantial lead in the number of ADHD clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the ADHD space is dominated by completed trials. Shire and Eli Lilly have the highest number of completed clinical trials for ADHD.

Key Topics Covered:

1 Key Takeaways

2 Disease Background

3 Treatment

4 Epidemiology

5 Pipeline Drugs

6 Marketed Drugs

7 Key Upcoming Events

8 Licensing And Asset Acquisition Deals

9 Parent Patents

10 Revenue Opportunity

11 Clinical Trial Landscape

12 Bibliography

13 Appendix

For more information about this report visit

View source version on

Business Wire

Last updated on: 09/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.